| All patients (n = 62) | FOLFOX + Cmab (n = 37) | XELOX + Cmab (n = 25) | P-value |
---|---|---|---|---|
No. women | 28 (45.2Â %) | 18 (48.9Â %) | 10 (40.0Â %) | 0.502 |
Median (range) age (years) | 66 (34–83) | 67 (45–83) | 66 (34–83) | 0.769 |
ECOG performance status | Â | Â | 0.885 | |
 0 | 55 (88.7 %) | 33 (89.2 %) | 22 (88.0 %) |  |
 1 | 7 (11.3 %) | 4 (10.8 %) | 3 (12.0 %) |  |
Primary tumor site | Â | Â | Â | 0.193 |
 Colon | 36 (58.1 %) | 18 (48.6 %) | 8 (32.0 %) |  |
 Rectum | 26 (41.9 %) | 19 (51.4 %) | 17 (68.0 %) |  |
Metastatic site | Â | Â | Â | Â |
 Liver | 47 (75.8 %) | 29 (78.4 %) | 18 (72.0 %) | 0.136 |
 Lymph node | 18 (29.0 %) | 13 (35.1 %) | 5 (20.0 %) |  |
 Lung | 15 (24.2 %) | 10 (27.0 %) | 5 (20.0 %) |  |
 Other | 8 (12.9 %) | 2 (5.4 %) | 6 (24.0 %) |  |